logo

Zai Lab Limited (ZLAB)



Trade ZLAB now with
  Date
  Headline
10/25/2019 8:36:49 AM Zai Lab Partner, MacroGenics Begin Phase 2/3 MAHOGANY Study Of Margetuximab In Gastric Junction Cancer
7/2/2019 7:35:18 AM Incyte And Zai Lab Announce Collaboration And License Agreement For INCMGA0012 In Greater China
6/11/2019 7:09:14 AM Deciphera Pharma And Zai Lab Announce Exclusive License Agreement For Ripretinib In Greater China
2/1/2019 7:30:53 AM Zai Lab Appoints Immuno-Oncology Pioneer, Lieping Chen, To Scientific Advisory Board
1/28/2019 7:33:58 AM Zai Lab Says CFDA Grants Priority Review Status To NDA For ZEJULA
1/9/2019 7:32:04 AM Zai Lab Completes Patient Enrollment Of Its Pivotal Trial Of Niraparib
12/28/2018 7:30:58 AM Zai Lab Announces Launch Of Optune In Hong Kong
12/12/2018 7:35:26 AM Zai Lab Announces Acceptance Of NDA Submission Of ZEJULA In Mainland China By NMPA
10/22/2018 7:35:16 AM Zai Lab Announces Approval Of ZEJULA For Patients With Relapsed Ovarian Cancer In Hong Kong
10/1/2018 8:12:58 AM Five Prime Therapeutics, Zai Lab Dose First Patient In Phase 3, Global Registrational Trial Of Bemarituzumab
9/27/2018 7:36:36 AM Zai Lab Appoints Industry Leader Tao Fu As President & COO, Expands US Presence
9/26/2018 7:36:14 AM Zai Lab Presents Interim Results Of Its Ongoing Phase 2 Study Of ZL-2301 (brivanib)
9/26/2018 7:34:36 AM Zai Lab Announces Positive Results Of Its Pharmacokinetics Study For ZL-2306 (niraparib)
9/12/2018 7:33:50 AM Novocure And Zai Lab Announce Collaboration With License Agreement For Tumor Treating Fields In Greater China
9/5/2018 9:20:01 PM Zai Lab Sells 7.50 Mln ADSs At US$20.00/ADS
8/28/2018 7:33:33 AM Zai Lab Doses First Patient In Phase III Trial Of ZL-2306 In Patients With Small-Cell Lung Cancer In China
  
 
>